Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Slack

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Oncogene|January 27, 2015
Junk DNA and the long non-coding RNA twist in cancer geneticsH Ling, K Vincent, M Pichler, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|October 12, 2005
Post-embryonic expression of C. elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive systemA Esquela-Kerscher, S M Johnson, L Bai, et al.
Molecular Microbiology|August 1, 1991
A Bacillus subtilis dipeptide transport system expressed early during sporulationC Mathiopoulos, J P Mueller, F J Slack, et al.
Nature|March 8, 2000
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegansB J Reinhart, F J Slack, M Basson, et al.
Oncogene|September 2, 2014
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancerA L Kasinski, K Kelnar, C Stahlhut, et al.
Oncogene|May 8, 2009
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cellsM Kato, T Paranjape, R U Müller, et al.
Oncogene|December 8, 2009
Regression of murine lung tumors by the let-7 microRNAP Trang, P P Medina, J F Wiggins, et al.
Oncogene|June 10, 2014
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancerX Chen, T Paranjape, C Stahlhut, et al.
Oncogene|December 2, 2010
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaS E Godshalk, T Paranjape, S Nallur, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Oncogene|January 27, 2015
Junk DNA and the long non-coding RNA twist in cancer geneticsH Ling, K Vincent, M Pichler, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|October 12, 2005
Post-embryonic expression of C. elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive systemA Esquela-Kerscher, S M Johnson, L Bai, et al.
Molecular Microbiology|August 1, 1991
A Bacillus subtilis dipeptide transport system expressed early during sporulationC Mathiopoulos, J P Mueller, F J Slack, et al.
Nature|March 8, 2000
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegansB J Reinhart, F J Slack, M Basson, et al.
Oncogene|September 2, 2014
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancerA L Kasinski, K Kelnar, C Stahlhut, et al.
Oncogene|May 8, 2009
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cellsM Kato, T Paranjape, R U Müller, et al.
Oncogene|December 8, 2009
Regression of murine lung tumors by the let-7 microRNAP Trang, P P Medina, J F Wiggins, et al.
Oncogene|June 10, 2014
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancerX Chen, T Paranjape, C Stahlhut, et al.
Oncogene|December 2, 2010
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaS E Godshalk, T Paranjape, S Nallur, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 2